Edgewise Therapeutics, Inc.: operating cash flow
Operating cash flow for Edgewise Therapeutics, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Edgewise Therapeutics, Inc. financial histories
What this measure means
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
Exact concept: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2020-01-01 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | -143,816,000 | USD | 2026-02-26 | 10-K · 0001104659-26-020112 |
| 2024-01-01 | 2024-12-31 | -109,028,000 | USD | 2026-02-26 | 10-K · 0001104659-26-020112 |
| 2023-01-01 | 2023-12-31 | -91,948,000 | USD | 2026-02-26 | 10-K · 0001104659-26-020112 |
| 2022-01-01 | 2022-12-31 | -52,635,000 | USD | 2024-02-22 | 10-K · 0001558370-24-001467 |
| 2021-01-01 | 2021-12-31 | -33,507,000 | USD | 2023-02-23 | 10-K · 0001558370-23-001895 |
| 2020-01-01 | 2020-12-31 | -14,634,000 | USD | 2022-02-24 | 10-K · 0001558370-22-001850 |
Related financial histories
- Edgewise Therapeutics, Inc.: total assets
- Edgewise Therapeutics, Inc.: total liabilities
- Edgewise Therapeutics, Inc.: stockholders equity
- Edgewise Therapeutics, Inc.: cash and cash equivalents
- Edgewise Therapeutics, Inc.: net income or loss
- Edgewise Therapeutics, Inc.: capital expenditure payments
- Edgewise Therapeutics, Inc.: financing cash flow
- Edgewise Therapeutics, Inc.: investing cash flow
- Edgewise Therapeutics, Inc.: retained earnings or deficit
- Edgewise Therapeutics, Inc.: basic weighted-average shares
- Edgewise Therapeutics, Inc.: diluted weighted-average shares
- Edgewise Therapeutics, Inc.: basic earnings per share
- Edgewise Therapeutics, Inc.: diluted earnings per share
- Edgewise Therapeutics, Inc.: income tax expense or benefit
- Edgewise Therapeutics, Inc.: net property, plant and equipment
- Edgewise Therapeutics, Inc.: share-based compensation expense
- Edgewise Therapeutics, Inc.: operating income or loss
- Edgewise Therapeutics, Inc.: current assets
- Edgewise Therapeutics, Inc.: current liabilities
- Edgewise Therapeutics, Inc.: current accounts payable
- Edgewise Therapeutics, Inc.: operating expenses
- Edgewise Therapeutics, Inc.: research and development expense
Inspect the source
- Entity
- Edgewise Therapeutics, Inc. / CIK 0001710072
- Captured
- 2026-09-21T17:24:47.450Z
- SEC response SHA-256
fdc3d3606ed30ad01dab6d3f276a5ede516c6d4ccc5eead9b5d5ab2ae15cce14
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001710072.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))